With a P/E ratio of 15, is this ASX All Ords share price too low to ignore?

I think this stock still has more to go.

| More on:
A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The All Ordinaries Index (ASX: XAO) share GQG Partners Inc (ASX: GQG) has risen strongly. Does it have a low enough price/earnings (P/E) ratio to buy?

GQG shares have risen 50% in the past six months, soundly outperforming the 6% increase for the S&P/ASX 200 Index (ASX: XJO).

The fund manager was very undervalued before, and I still think the ASX All Ords share is undervalued now, following continued growth.

Why 2024 looks like another good year for the All Ords ASX share

The funds management space is difficult for the industry as a whole. Low-cost exchange-traded funds (ETFs) are capturing a lot of investment inflows.

However, not all fund managers are suffering, GQG is one of the rare ones doing very well.

In the 2023 full-year result it reported net flows of US$10 billion, a 14.7% increase of the average funds under management (FUM) to US$101.9 billion, a 17.4% rise in distributable earnings to US$297.9 million and a 17.3% rise in the dividend per share to US 9.1 cents per share.

Those numbers are impressive, but they tell us about the past. What about the future?

The average FUM for 2023 was US$101.9 billion and closing FUM at December 2023 was US$120.6 billion. That implies an 18% increase of FUM, if the FUM weren't to change. But, it has changed – FUM at January 2024 was US$127 billion (with net inflows of US$1.9 billion), 24.6% more than 2023's average FUM.

Unless there's a sustained crash of the global stock market, it seems GQG is on track to report an increase in earnings (and the dividend) of more than 20%.

Fund managers are typically scalable businesses – if FUM rises by 10%, it doesn't require 10% more employees or 10% more office space to manage that increased capital. Profit margins can rise as FUM grows.

Cheap valuation

If we assume a 20% rise in EPS for the ASX All Ords share in 2024, it would put the GQG share price at under 13 times FY24's possible earnings with a potential dividend yield of 7.6%.

I'm not going to assume that GQG's FUM can grow forever, but for the next year ahead it still looks undervalued with how well its investment funds are performing and how much it's bringing in with net inflows.

If the ASX All Ords share can keep increasing its geographical footprint and winning new clients, it may have an extended growth runway that the market isn't appreciating. The attractive flow of dividends is helping boost returns.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

Four piles of coins, each getting higher, with trees on them.
Growth Shares

2 ASX 200 shares that could be top buys for growth

These two businesses have an exciting future.

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
Technology Shares

This ASX 200 share is being labelled one of the market's most undervalued by brokers

NextDC shares have pulled back sharply, but brokers believe the long-term growth story remains firmly on track.

Read more »

Hand holding out coal in front of a coal mine.
Energy Shares

Up 25% in 2025: Is Whitehaven Coal still a buy?

After a strong 25% run this year, investors are asking whether Whitehaven Coal still has more upside left.

Read more »

Five guys in suits wearing brightly coloured masks, they are corporate superheroes.
Opinions

5 ASX shares I'd buy with $10,000 this week

These are the ASX stocks I have my eye on this week.

Read more »

bull market model with a bull looking at a rising chart
Opinions

By December 2026, $1,000 invested in EOS shares could be worth…

With its share price taking off and contracts piling up, EOS is shaping up as one of the most compelling…

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

People with their hands underneath each other's hands holding a plant.
Growth Shares

2 ASX growth shares I'd buy today for growth and income

Both of these businesses are delivering excellent progress.

Read more »